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Abstract
Autophagy, particularly with BECN1, has paradoxically been highlighted as tumor promoting
in Ras-driven cancers, but potentially tumor suppressing in breast and ovarian cancers.
However, studying the specific role of BECN1 at the genetic level is complicated due to its
genomic proximity to BRCA1 on both human (chromosome 17) and murine (chromosome
11) genomes. In human breast and ovarian cancers, the monoallelic deletion of these genes
is often co-occurring. To investigate the potential tumor suppressor roles of two of the most
commonly deleted autophagy genes in ovarian cancer, BECN1 and MAP1LC3B were
knocked-down in atypical (BECN1+/+ and MAP1LC3B+/+) ovarian cancer cells. Ultra-per-
formance liquid chromatography mass-spectrometry metabolomics revealed reduced levels
of acetyl-CoA which corresponded with elevated levels of glycerophospholipids and sphin-
golipids. Migration rates of ovarian cancer cells were increased upon autophagy gene
knockdown. Genomic instability was increased, resulting in copy-number alteration patterns
which mimicked high grade serous ovarian cancer. We further investigated the causal role
of Becn1 haploinsufficiency for oncogenesis in a MISIIR SV40 large T antigen driven spon-
taneous ovarian cancer mouse model. Tumors were evident earlier among the Becn1+/-
mice, and this correlated with an increase in copy-number alterations per chromosome in
the Becn1+/- tumors. The results support monoallelic loss of BECN1 as permissive for
tumor initiation and potentiating for genomic instability in ovarian cancer.
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Author summary
Life requires an excellent trash and recycling system. One system mammalian cells rely
upon is called autophagy. Autophagy clears cells of larger forms of debris and is critical
for normal cell function. We previously found that ovarian cancer cells are unable to exe-
cute normal cellular recycling during periods of stress, due to losses in core autophagy
genes. Since autophagy has previously been implicated as a cancer cell survival factor, we
directly investigated the impact of autophagy gene loss in ovarian cancer models. We dis-
covered a reduction in autophagy proteins disabled normal genome quality control during
cell division, leading to genomic instability. We document here for the first time whether
reducing an autophagy gene in mice influences ovarian tumor formation. We found ear-
lier ovarian tumors in autophagy deficient mice compared with control mice. We con-
clude that serous ovarian carcinomas, which rank among the most genetically altered
cancers, gain their hallmark genomic instability in part by losing autophagy genes.
Introduction
The role of autophagy in cancer remains enigmatic. The canonical cellular task of autophagy is
to recycle damaged proteins, organelles, and fatty acids [1]. For protein quality control, autop-
hagy is partially redundant and complementary to other cellular homeostasis pathways, such
as the endoplasmic reticulum stress response and the ubiquitin-proteasome system. Due to its
central role in recycling metabolites, especially in hypoxic tumor environments, autophagy has
been demonstrated to aid in tumor progression [2]. The role of autophagy as a tumor promot-
ing cellular pathway is particularly evident in Ras- or Raf-driven tumors. Complete deletion of
Atg7, an essential autophagy gene, dramatically slows tumor growth in these mouse models [3,
4]. This is in part due to depleted pools of glutamine and glutamate preventing nucleotide syn-
thesis [5]. However, autophagy has also been described as a tumor suppressor pathway. Its role
in protein quality control affects multiple homeostatic mechanisms, many of which interact
with DNA repair pathways [6–8]. BECN1, also known as beclin 1 [9], has been highlighted for
its tumor suppressor roles ever since two independent labs generated heterozygous whole-
body knockout mouse models; each study observed earlier cancer formation in Becn1+/- mice
compared to Becn1+/+ mice [10, 11].
Tumor suppressor gene deletions require additional modulators to form cancer. In human
breast cancer and ovarian cancer BECN1 is almost always co-deleted with BRCA1. This led to
the assumption that BECN1 loss is a passenger event and is only deleted due to its proximity to
BRCA1 [12]. Recent experiments and genomic analyses have suggested that moderate tumor
suppressors are actually co-deleted with adjacent or distant tumor suppressors during cancer
evolution, such as those near TP53 on chromosome 17 [13]. For these TP53-co-deletions,
some, such as EIF5A and ALOX15B, act in an independent fashion to suppress tumor forma-
tion. BRCA1 deletions similarly involve BECN1. In human breast cancers, reduced expression
of BECN1 at the RNA level indicated a poor prognosis [14]. Re-expression of BECN1 in a het-
erozygous deleted BECN1 human breast cancer cell line MCF7 reduced clonogenicity in soft
agar [15]. Aside from BECN1, few haploinsufficient models of autophagy have been studied in
the context of cancer.
Our prior bioinformatic studies suggest that monoallelic deletions in autophagy genes are
unusually pervasive in high-grade serous ovarian cancer (SOC) (98% of tumors have multiple
heterozygous deletions), although these heterozygous deletions are present in many other can-
cer types. Homozygous deletions are exceedingly rare (<1% of genes in any tumor type) [16].
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We previously found that monoallelic deletions in autophagy genes suppressed the ability of
ovarian cancer cells to overcome proteotoxic stress. These deletions similarly limited autop-
hagy induction. Upon autophagic stress, ovarian cancer cells selectively perished without the
need for programmed cell death via apoptosis or necroptosis, resulting in a low-toxicity treat-
ment [17]. Considering that completely compromising autophagic flux via homozygous dele-
tion of autophagy genes can prevent tumor formation, it was unclear why tumors might arise
while lacking so many autophagy alleles. One possibility is that dysregulation of this homeo-
static pathway involved in DNA repair could lead to genomic instability. Heterogeneity has
been linked to poor patient outcome [18]. Notably, SOC has among the greatest intra-tumor
clonal heterogeneity in a pan-cancer analysis [19].
To investigate the effects of BECN1 haploinsufficiency in ovarian cancer, we developed a
pseudo-haploinsufficiency knockdown model using a human ovarian cancer cell line that is
atypically autophagy-competent. BECN1 or MAP1LC3B gene suppression resulted in increases
in copy-number genomic instability. Extending these studies in a murine spontaneous ovarian
cancer model, we found that tumors initiate earlier in Becn1+/- mice relative to Becn1+/+ lit-
termates. Becn1+/- murine tumors and autophagy suppressed human ovarian cancer cell lines
displayed greater rates of chromosomal aberrations.
Results
Genetic context of BECN1 deletions
Since the vast majority of genetic deletions in solid tumors are monoallelic, we queried The
Cancer Genome Atlas (TCGA) data for mutations and heterozygous losses in BECN1 and
BRCA1 using cBioPortal [20] and PanCancer Atlas data. In both SOC (OV) and breast cancer
(BRCA), the frequency of monoallelic deletions of either BECN1 or BRCA1 was>10-fold that
of the frequency of single-nucleotide variant or insertion-deletion mutations (Fig 1A). This is
consistent with the hypothesis that monoallelic deletions predominantly act to reduce the
expression levels of tumor suppressor genes [21, 22], rather than to achieve a loss-of-heterozy-
gosity event complementing a point mutant. The concordance of BRCA1 deletions and
BECN1 deletions between tumor types is expected from their close proximity on chromosome
17 (Fig 1B). The significance of exclusive deletions of only BECN1 in human breast and ovar-
ian cancer has been debated [12, 14]. However, to directly evaluate whether single copy-num-
ber alteration (CNA) events overlapped both genes, further bioinformatic analysis was
undertaken.
CAIRN: A tool to easily visualize and quantify copy-number alterations
The genetic lesions causing CNAs often overlap two or more tumor suppressor genes and
oncogenes [21]. To readily visualize these changes, we created a bioinformatic tool to enable
researchers without a bioinformatics background to readily test for gene co-deletion or co-
amplification. The tool, “Copy Alterations Intuitive-Rendering Navigator” (CAIRN), permits
stacked visualization of genetic gain or loss events not unlike the similarly-named stacked
stone markers. CAIRN works with custom CNA datasets, queries of chromosome regions, and
gene-centric queries. It can output segments which overlap the region(s) of interest or output
segments which end at a region of interest (for example, telo-centric CNAs). The tool is avail-
able online at https://delaney.shinyapps.io/CAIRN/.
Data from 33 TCGA-PanCancer Atlas tumor types were uploaded into the public CAIRN
database. We validated the program using the PTK2 and MYC oncogenes, which are known to
be co-amplified on Chromosome 8 [23]. Oncogenes on the same locus may co-promote tumor
initiation and progression. Co-amplification CNAs of these oncogenes were prevalent in
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ovarian and breast cancer (S1 Fig). Quantitative analysis paired with the qualitative visualiza-
tion of the CNAs by CAIRN will be useful for chromosome-localized gene pairs or gene sets.
It is believed that tumor deletion CNAs are selected to encompass multiple tumor suppres-
sors (Fig 1D and 1E) [21]. A query for CNAs overlapping BECN1 and/or BRCA1 in ovarian
cancer and breast cancer confirmed that BECN1 is occasionally exclusively deleted (no co-
deletion of BRCA1, 8 of 594 tumors for ovarian cancer and 4 of 1085 for breast cancer).
Fig 1. CAIRN analysis of co-alteration of BECN1 and BRCA1. A, Single-nucleotide variants or insertion deletion rates for the adjacent genes BECN1 and BRCA1 are
compared for the SOC (OV) and breast cancer (BRCA) datasets. Monoallelic loss rates are shown for comparison. B, Ensembl display of genomic region on Chr17
encompassing BECN1 and BRCA1. C-F, A visualization tool CAIRN was developed to enable the oncology community to easily analyze and display copy-number
alterations in human datasets (see Materials). Each horizontal segment is from an individual tumor and displays a continuous CNA of the chromosome. Blue segments
represent copy-losses, red segments indicate copy-gains, and both are displayed in relation to the parent chromosome indicated in grey. Human TCGA tumors were
tested for CNAs overlapping the genes BECN1 and BRCA1. Ovarian tumors with exclusive BRCA1 or BECN1 deletions (C) are far rarer than tumors deleted in both
genes (E) as shown by CAIRN. Breast tumors followed a similar pattern (D,F). In both tumor types, BECN1 deletions without accompanying BRCA1 deletions were
found.
https://doi.org/10.1371/journal.pgen.1008558.g001
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BRCA1 is occasionally exclusively deleted even less frequently (3 of 594 for ovarian cancer and
4 of 1085 for breast cancer) (Fig 1C and 1D). However, the vast majority of deletion segments
are deleted for both (361 of 594 for ovarian cancer and 277 of 1085 for breast cancer), as might
be expected from the hypothesis that tumor deletion CNAs are selected to encompass multiple
tumor suppressors (Fig 1D and 1E) [21]. In summary, BECN1 is found to be deleted indepen-
dently of BRCA1 in some ovarian and breast tumors, although the majority delete BECN1 and
BRCA1 concomitantly.
Clinical and genetic characteristics associated with autophagy gene loss
More than 95% of human ovarian cancers have deletions in 4 or more autophagy genes [16].
These include those encoding beclin 1 and the autophagosome biogenesis and cargo recruit-
ment protein MAP1LC3B (simply, LC3B). LC3B is used as a reporter in the majority of cellular
assays to measure quality and quantity of autophagy [9], and LC3B is heterozygous deleted in
~68% of SOC tumors and ~56% of breast tumors (S2 Fig). It is noteworthy that these occur as
heterozygous deletions >99% of the time, not homozygous deletions, so a residual level of
autophagy persists. To address the possibility that these deletions arise in specific patient popu-
lations, those patients with BECN1 or LC3B tumor deletions were queried for clinical charac-
teristics. Gene loss was not associated with race (S3A Fig), stage (S3B Fig), age (S3C Fig), nor
somatic mutation burden (S3D Fig). However, the loss of either BECN1, LC3B, or both was
associated with a higher percentage of CNA alterations within the tumor (S3E Fig). While
individual gene loss did not confer significantly better or worse response to standard of care
(S3F Fig), suppression of gene expression conferred slightly worse prognosis for BECN1 (S2G
Fig, P< 0.02) and a trend toward worse prognosis for LC3B (P< 0.067). Overall survival was
also significantly worse in patients with a low HAPTRIG autophagy pathway score (S3H Fig,
P< 0.043) [16]. The results suggest that the increased overall autophagy gene loss in low scor-
ing tumors, relative to higher scoring tumors, impacts patient outcomes.
Autophagy in ovarian cancer cells knocked-down in BECN1 and LC3B
Among the ovarian cancer cell models available for study, no high-grade serous ovarian cancer
cell lines have a perfectly diploid level of all autophagy genes. This complicates the selection of
cell lines to study autophagy, as it is technically infeasible to revert to diploid each one of 4–12
lost autophagy alleles in high-grade serous ovarian cancer cell lines. To define appropriate
models to study suppression of BECN1 or LC3B, a flow cytometric analysis of acridine orange
accumulation in widely used cell lines was performed. Acridine orange becomes protonated
and unable to pass through lipid membranes when it enters an acidic compartment such as
lysosomes, autophagic vacuoles, and amphisomes [9]. In parallel, the level of autophagy
genetic suppression in each cell line was predicted by HAPTRIG [16], which uses cell line gene
deletion information, protein-protein interaction data, and haploinsufficiency phenotypes. A
strong correlation (R2 = 0.99) between acidic compartment accumulation and HAPTRIG-pre-
dicted suppression of autophagy genes was found (Fig 2A), suggesting monoallelic changes
predictably contribute to the disruption of organelles essential for autophagy.
The cell lines best able to accumulate acidic vacuoles were IGROV1 and SKOV3 cells.
IGROV1 is a hyper-mutated mixed lineage cell line with a Y126C p53 mutation. SKOV3 is a
histologically serous cell line which does not express p53 [24]. Neither cell line contains dele-
tions in BECN1 nor LC3B (S4 Fig), permitting their use in controlled autophagy gene knock-
down studies. To phenocopy haploinsufficiency, we selected shRNAs targeting BECN1 and
LC3B whose expression resulted in intermediate reduction of protein expression. We focused
on two shRNAs whose impact was neither complete nor minimal, but as close to a 50% target
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as possible within the suite of shRNAs we tested [16]. These shRNAs were confirmed to mod-
erately knock down their target gene in SKOV3 (Fig 2B) and IGROV1 (Fig 2C) cells.
The direct manipulation of LC3B complicates the study of autophagic flux. Commonly
used flux assays involve observing the conversion of LC3-I to LC3-II or introducing a tagged
(RFP-)GFP-LC3B. The latter method confounds the interpretation of effects since the tagged-
LC3B would be predicted to rescue shRNA knockdown. The former is complicated since autop-
hagic measurements compare LC3B to a control protein. To study acidic recycling compart-
ments independent of individual autophagy or lysosomal proteins, an acridine orange staining
assay was performed. This does not measure autophagic flux specifically [9], but rather turnover
of all acidic organelles within the cell. SKOV3 cells were blocked from autolysosome resolution
using chloroquine, induced for autophagy using the mTORC1 inhibitor rapamycin, or both
(S5A Fig). As expected, SKOV3 cells knocked-down in BECN1 or LC3B both exhibited signifi-
cantly reduced acidic punctae staining relative to scrambled control shRNA in all conditions
(S5B Fig). Similar results were found using IGROV1 cells (S5C and S5D Fig). This result con-
trasts with previous findings in which knockdown of BECN1 does not necessarily reduce LC3
lipidation [25]. In summary, autophagy markers and acidic organelle recycling were decreased
in SKOV3 and IGROV1 cells in both the shBECN1 and shLC3B conditions.
Oncogenic phenotypes from autophagy gene knockdown
We next evaluated potential roles for BECN1 and LC3B in suppressing known oncogenic
phenotypes. Since autophagy is a catabolic pathway, metabolomics were performed on knock-
down cells to determine alterations in metabolism by ultra-performance liquid chromatogra-
phy mass-spectrometry (UPLC-MS/MS) (S6A and S6B Fig). The most significant changes
were found in lipid metabolism. Acetyl-CoA levels were reduced to 26% or 39% of control in
shLC3B and shBECN1 cells, respectively (Fig 3A). This may result from an increase in anabolic
lipid metabolism, as a concomitant increase of 2.2–3.7-fold was observed for glycerophospho-
lipids and sphingolipids (Fig 3B). These lipids are required for new membrane formation dur-
ing cellular proliferation, and glycerophospholipid synthesis is proposed as a drug target for
Fig 2. Titrated knockdown of BECN1 or LC3B reduces autophagosome accumulation markers. A, Commonly used ovarian cancer
cell lines were tested for acidic vacuole accumulation following chloroquine treatment (10μM 24h) by flow cytometric measurement of
acridine orange (AO). Shown are the averages of 4 flow cytometry assays. The x-axis depicts a pathway network calculation from
HAPTRIG defining the levels of autophagy pathway haploinsufficiency within each cell line due to monoallelic losses of KEGG
autophagy pathway genes. B, SKOV3 cells, which do not have losses in BECN1 nor LC3B, were stably knocked-down by shRNA
lentivirus. A western blot was performed for the targets LC3B and BECN1, along with GAPDH loading control. C, IGROV1 cells were
similarly assayed.
https://doi.org/10.1371/journal.pgen.1008558.g002
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cancer [26]. Canonical energy signaling molecules ATP, ADP, AMP, and cAMP were largely
unchanged (S6C Fig), with the exception of a 13% increase of ADP in shLC3B cells. A reduc-
tion in free amino acids may be predicted from a reduction of autophagy, yet this was not
observed in SKOV3 cells (S6D Fig). Putricine levels were 2.7 times shScr levels in shLC3B
cells, while downstream metabolites spermidine and spermine levels were elevated but not sig-
nificantly increased (S6E Fig). CoA (S6F Fig), NAD+, and both oxidized and reduced forms of
glutathione were unchanged. (S6G Fig). Thus, autophagy gene suppression altered lipid
metabolism but not canonical energy metabolites.
In parallel, we tested a CRISPR-Cas9 total knockout of LC3B (S6H Fig). Notably, the total
disruption of this autophagy gene yielded a metabolism distinct from the impaired but func-
tioning system in the shLC3B and shBECN1 cells (S6I and S6J Fig). This finding is consistent
with the notion that dose-dependent decreases in autophagy yields a markedly different phe-
notype than a total knockout, which provides one explanation as to why homozygous loss
rarely occurs in tumors.
Autophagy is implicated in focal adhesion turnover and cell migration via recruitment of
paxillin to LC3 or by recruitment of the selective autophagy cargo receptor NBR1 [27, 28].
Only marginal changes were observed in IGROV1 migration, which exhibits poor motility
(S7A and S7B Fig), Notably, the migration-competent SKOV3 cells showed a marked accelera-
tion of motility upon LC3B (52% faster) or BECN1 knockdown (51% faster) (Fig 3C and 3D).
Genomic instability is a hallmark of cancer [29], with SOC specifically containing some of the
highest rates of chromosome instability of any cancer. To determine if genomic instability, and
resultant heterogeneity, was altered among cells with deficient autophagy, SKOV3 cells were
tested for an increase in stochastic DNA lesions, in particular ssDNA and dsDNA breaks, by alka-
line comet assay [30]. However, no differences in tail moments were observed in autophagy
knockdown SKOV3 cells (S7C Fig), suggesting a grossly similar incidence of lesion occurrence.
Defective cell division can lead to aneuploidy. We reasoned that since BECN1 or other
autophagy gene loss may promote centrosome instability [31], our shBECN1 and shLC3B cells
may contain an unusual complement of centrosomes. Surprisingly, most cells had a single cen-
trosome spot. No cell contained three distinct centrosomes (N > 100 cells per condition), nor
were differences in centrosome size observed (S7D Fig). However, anaphase bridge formation
occurred twice as frequently among autophagy deficient cells (Fig 3E). This was independent
of BRCA1 level, since BRCA1 expression was constant among autophagy competent or defi-
cient cells (S7E Fig). γH2AX foci were similarly increased in shLC3B and shBECN1 SKOV3
cells (Fig 3F and 3G), but not in IGROV1 cells (S7 Fig). Foci levels in shLC3B and shBECN1
cells were comparable to cisplatin-induced stress. Taken together, decreases in BECN1 or
LC3B protein are sufficient to manifest genomic instability and increased migration, two hall-
marks of aggressive tumors.
Autophagy gene knockdown increases chromosome instability
To quantify whether DNA-bridging and γH2AX foci contributed to genomic instability in
SKOV3 cells, we transduced and passaged four populations of SKOV3 cells for 30 passages in a
Fig 3. Knockdown of LC3B or BECN1 increases oncogenic phenotypes. A-B, SKOV3 cells transduced by the
indicated lentivirus were assayed by metabolomics. Quantitation of the indicated metabolites is shown. C, Confluent
SKOV3 cells were tested for migration rates using a scratch-wound assay. D, Quantitation of three independent
wound closure experiments. E, Dividing SKOV3 cells were imaged for DNA content, blinded, and scored for anaphase
bridge formation. CP denotes cisplatin use. N is the number of anaphases analyzed from three independent assays. F,
SKOV3 cells were imaged for γH2AX puncta. N> 900 cells per condition from two independent assays. G,
Quantitation of (F). � indicates P� 0.05, ��P� 0.01, ���P� 0.001.
https://doi.org/10.1371/journal.pgen.1008558.g003
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genetic drift assay (Fig 4A). After 30 passages, to our surprise, there was no increased expres-
sion of LC3B or beclin 1 in our cells. Thus, under standard tissue culture conditions, there is
no overt selection pressure to restore autophagy despite documented metabolomic changes
(Fig 4B and 4C). High resolution Oncoscan arrays (>220,000 genomic targets) were used to
assess de novo CNAs [32]. For statistical purposes of comparing experimental to control sam-
ples, the reduced segment method was used [33]. Unbiased hierarchical clustering of these
CNAs separated shBECN1 and shLC3B from shScr controls (Fig 4D). The Euclidean distance
of these CNAs, which is a measure of genetic drift, was higher between all autophagy-sup-
pressed pairs than variation amongst the controls (Fig 4E). The greater genetic drift between
autophagy-suppressed samples was evident independent of normalization to the control. Since
both focal and megabase scale changes were observed, we tested whether the edges of these
CNAs originated from known unstable DNA regions in cancer cells (see Methods for refer-
ences). Interestingly, BECN1 knockdown cells were enriched for telomeric and intragenic
breaks (Fig 4F), while LC3B knockdown cells were enriched in centromeric, intragenic, and
fragile site breaks. However, it is noteworthy that “stable” chromatin also had elevated rates of
CNA formation in both autophagy gene knockdown groups, suggesting breaks were not
explained only due to chromosomal fragility.
BECN1 knockout can result in gross aneuploidy in multiple model systems [34, 35]. To
evaluate more subtle copy-number changes, we annotated the CNAs by chromosome location
and base-pair length according to genotype. Subtle CNA variation was observed for shScr con-
trol SKOV3 cells across the genome for focal (<100kb) CNAs, but was rare for large (>1Mb)
CNAs. There was a significant increase in both focal and large CNAs in shBECN1 cultures (S8A
Fig). However, some chromosomes were more unstable than others (S8B Fig). LC3B knock-
down exhibited similar disruption of both focal and large CNAs. Shared alterations included
telomeric 9p (amplified in 7 of 8 shBECN1 and shLC3B cultures), chromosome arm 11p
(amplified in 7 of 8 shBECN1 and shLC3B cultures), and centromeric chromosome 2 (deletions
in 8 of 8 shBECN1 and shLC3B cultures). Deletions in chromosome arm 14p were shared across
shLC3B cultures but not shBECN1 cultures, as were 15q deletions. In 3 of 4 shBECN1 cultures
but only 1 of 4 shLC3B cultures, deletions within 21q were observed (summarized in S1 Table).
Common break sites lay within exceptionally long genes [36]. The patterns of CNA breaks
and regions were checked for repetitive patterns and random effects. Since we identified an
increase in intragenic dsDNA breaks in our SKOV3 autophagy-compromised cells, we won-
dered if the same pattern was observed. While very few previously identified genes were dis-
rupted by CNA formation in our evolved SKOV3 cells (S1 Table), we did observe a similar
bias toward increased length, but not expression, in genes harboring genomic breaks (Fig 4G
and 4H). To investigate whether this was significant, we performed a permutation analysis to
determine if simply by having completely random CNAs of the same size as we observed in
our samples, similar results would be found. In fact, randomized CNAs of equal length to the
observed CNAs were observed more frequently on large genes relative to the actual distribu-
tion of gene sizes in the human genome (Fig 4G and 4H). Therefore, our observations are not
explained by genomic breaks which occur during the transcriptional regulation of long or
active genes. To further evaluate the level of randomness, reduced segment CNAs were com-
pared between shScr cells and autophagy gene knockdown cells. The ratio of single-sample
unique CNAs to shared (potentially non-random, found in at least two samples) CNAs was
found to be 1.5 in shScr isolates (Fig 4I), while in shBECN1 this ratio was 3.1 (Fisher’s exact
P< 3.8 x 10−4) and 3.5 in shLC3B (P< 2.5 x 10−5). Randomness was not different between
shBECN1 and shLC3B cultures (P< 0.42). Thus, while there are more overall shared segments
within autophagy gene knockdown cells, there is an even greater increase in randomly
changed CNAs.
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Pathway analysis of CNAs
To determine patterns that were consistently altered in the shBECN1 and shLC3B cells com-
pared to controls, we used two pathway analysis tools: HAPTRIG [16] and GSEA [37]. GSEA
is a commonly used tool to measure curated sets of genes which are altered at statistically
improbable rates, whereas HAPTRIG further incorporates interaction and haploinsufficiency
data to generate pathway network scores, outperforming GSEA at identification of tumor sup-
pressors and oncogenes using cancer CNA data [16]. Here, KEGG pathway sets were used,
since KEGG is one of the few pathway sets containing “autophagy” as a discrete pathway. We
have reasoned that if the suppression of autophagy confers an adaptive selection event, individ-
ual gene deletion may not be as important as the ultimate functional impact on the autophagy
pathway. Indeed, among patients the genes deleted within the autophagy pathway vary widely
from tumor to tumor.
Similar to how tumor data is analyzed, results from shBECN1 and shLC3B knockdown cul-
tures were pooled as a cohort (“shAUTO”) and compared to shScr control cultures. HAPTRIG
analysis identified 29 differentially altered pathways in shBECN1/shLC3B cultures relative to
shScr, at a significance of P� 0.05 as appropriate to the small sample size. Notably, many of
the differentially altered pathways in SKOV3 shAUTO cells were altered concordant with that
observed human ovarian tumors studied by the TCGA (filled circles in Fig 5A). Fanconi-ane-
mia, RNA degradation, regulators of NOTCH signaling, and TNF signaling were all allelically
suppressed (Fig 5A; S1 Table). Differentially altered pathways that were copy-number upregu-
lated included the glycerolipid metabolism pathway, which was previously found as one of the
most upregulated pathways in SOC [16]. Endocytosis, PI3K-Akt signaling, and central carbon
metabolism in cancer were upregulated, further recapitulating pathways upregulated in
human ovarian cancer. Complementary GSEA identified by P< 0.05 the copy-number upre-
gulation of glycolysis, along with autophagy, toll-like receptor signaling, and cytosolic DNA
sensing. HAPTRIG was used to tabulate which genes contribute the most to pathway alter-
ations. Many of the same gene CNA hubs in human ovarian tumor networks are marked as
hubs in the autophagy deficient cohort (shAUTO, Fig 5B). Taken together, these results indi-
cate that moderate suppression of single autophagy genes can result in a strikingly altered
genotype. Passaging the cells in culture without any phenotypic selection unexpectedly yielded
pathway-level alterations that recapitulate those observed in human disease.
Haploinsufficient Becn1 ovarian cancer mouse model yields early tumors
While co-deletion of BECN1 with the well-established tumor suppressor BRCA1 occurs in the
vast majority of BRCA1 deletion CNAs (Fig 1E), BECN1 has not been directly tested as a
tumor suppressor in the context of ovarian cancer. Given the role of autophagy in suppressing
Fig 4. Spontaneous copy-number evolution in ovarian cancer cells. A, SKOV3 cells were stably knocked-down by shRNA lentivirus. Control,
shBECN1, and shLC3B cultures were passaged 30 times (1:3 dilutions) with no selective pressure other than transgene selection. Genomic DNA was
then harvested. B, SKOV3 remained knocked-down for target protein expression at the completion of the experiment. For early passage knockdown
levels, please refer to Fig 2 and S6 Fig. C, Quantitation of western blot data. LC3-II is separately quantified from total LC3 to provide independent
estimates of knockdown efficiency and autophagosomal LC3. D, Copy-number alteration profiles of SKOV3 transduced with shBECN1 or shLC3B,
arranged by chromosome on the x-axis as indicated. Red coloration depicts copy-number gains while blue coloration depicts copy-number losses,
relative to shScr controls. Hierarchical clustering of copy-number data was performed, resulting in separation of autophagy-knockdown cells from
controls. E, Euclidian distance metrics of copy-number alterations is compared between the genotypes. All autophagy knockdowns were more
dissimilar from one another than the scrambled controls. F, Common break points normally found in tumor samples were compared to break points
of copy-number changes in SKOV3 cells. G-H, CNA edges of SKOV3 cells suppressed in autophagy (shBECN1 and shLC3B combined) were
overlaid with genes and analyzed for (G) gene size and (H) expression level. While expression level did not predict gene breakage, larger genes were
more often disrupted by CNA break points. However, this would be expected by chance, as shown by 1,000 randomizations of the observed CNAs
(“Expected” plot). I, Fisher’s exact test tables comparing CNA segments that are shared between knockdown cells and scrambled control cells. �
indicates P� 0.05, ��P� 0.01, ���P� 0.001, ns P> 0.05.
https://doi.org/10.1371/journal.pgen.1008558.g004
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chromosomal instability, it was not unreasonable that BECN1 might act as a tumor suppressor.
We investigated this using a spontaneous mouse model of ovarian cancer which recapitulates
the inactivation of p53, a characteristic of the aggressive serous histotype [38–40]. The SV40
large T antigen driven by the MISIIR promoter inactivates p53 and other cell cycle regulators
[41] in the ovarian and fallopian epithelium [42]. Mice expressing this transgene begin to
exhibit ovarian tumors around 16–22 weeks of age.
We crossed Becn1 heterozygous knockout females (Becn1+/-) with TAg males. The result-
ing litters are a mix of the expected four genotypes, and we compared female "BTAg" (Becn1
+/- MISIIR SV40 Large T Antigen) mice to littermate "TAg" (Becn1+/+ MISIIR SV40 Large T
Antigen) females. We performed ultrasounds on a cohort of mice for ovary size at 12 weeks: a
time point in which TAg mice have not been observed to form tumors. Ultrasound size mea-
surements indicated significant hypertrophy of ovaries in Becn1+/- TAg mice, but not in
Fig 5. CNA patterns affect SOC pathways. A, HAPTRIG pathway analysis of SKOV3 copy-number alterations. Nominally significant (P< 0.05)
pathways enriched for suppression or elevation of CNAs in SKOV3 autophagy suppressed cells (shBECN1 and shLC3B combined, “shAUTO”) by the
gene-set analysis tool HAPTRIG are displayed as red (elevated) or blue (suppressed). Open colored circles indicate pathways only found in SKOV3 cells,
and closed colored circles indicate pathways also found to be similarly dysregulated in TCGA studied serous ovarian cancer primary tumors (OV). B-C,
Select altered pathways from TCGA serous ovarian cancer data are highlighted and networks were graphed by HAPTRIG. Scores were tabulated and
those gene nodes with scores one z-score away from the median node score are displayed with blue if suppressed and in red if elevated. Edges indicate
physical interactions as found in BioGrid. Boxes were drawn around genes if HAPTRIG found this node to be one of the top five influential genes
(suppression and elevation were separately tested) within the selected pathway for both the SKOV3 experiment and TCGA ovarian cancers.
https://doi.org/10.1371/journal.pgen.1008558.g005
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Becn1+/+ TAg controls (Fig 6A–6C). Early tumor initiation was confirmed by dissection and
harvest of part of the cohort (Fig 6B), suggesting that impaired autophagy promotes or sup-
ports tumor initiation. Despite earlier tumors and a trend toward early morbidity, no signifi-
cant difference in morbidity was observed between Becn1+/+ and Becn1+/- groups as the
remaining mice were aged (S9 Fig), possibly as a result of insufficient cohort size. Large
tumors, ascites, or ruptured ovaries were observed in 100% of the euthanized mice. Genomic
instability (Fig 4) provided a possible mechanism for enhanced tumorigenesis in BTAg mice.
To test if the tumors forming in BTAg mice had higher rates of chromosome instability, we
dissected ovaries from mice requiring euthanasia from the morbidity study. We collected adja-
cent uterine tissue as a normal genomic control. Dissected samples were then processed to
purify genomic DNA and whole-genome sequenced to low-pass coverage by NGS. Copy-num-
ber alterations present in each chromosome for each sample were then calculated and tabu-
lated. No deletion of Brca1 was observed. (S9 Fig, S3 Table). Overall rates of CNAs were low
Fig 6. Becn1+/- mice present early ovarian tumors. A, Ultrasound images of tumor size at 12 weeks of age in the MISIIR Large-T-Antigen (TAg+) ovarian
cancer mouse model. Example tumors for each genotype are shown for both left (L) and right (R) ovaries. Non-TAg+ controls are shown for comparison. B,
Example 12-week tumors are shown and juxtaposed with an image of the mouse model, with characteristic large ears (TAg model) and brown fur coat (Becn1+/-
model). C, Quantitation of all mice studied for ovarian size at 12 weeks of age. N = 13 for Becn1+/- TAg+, N = 14 for Becn1+/+ TAg+ mice. Wilcoxon rank-sum
test was used to determine the P-value. D, Terminal ovarian tumors were isolated for genomic DNA and assayed by whole-genome sequencing. Becn1+/-
tumors displayed higher rates of CNAs per chromosome. Two outlier chromosomes are labeled for CNA counts beyond the edge of the y-axis. N = 4 mice per
group for whole-genome copy-number analysis; each data point represents one chromosome. Wilcoxon rank-sum test was used to determine the P-value.
https://doi.org/10.1371/journal.pgen.1008558.g006
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for these TAg murine tumors (median of 1 CNA per chromosome), despite histology that is
otherwise similar to high grade serous ovarian cancer [42]. Nonetheless, BTAg mice had sig-
nificantly higher CNAs per chromosome than control TAg mice (2.78 vs 0.68, P< 0.003 by
Wilcoxon rank-sum test) (Fig 6D, S10 Fig). Overall, loss of one allele of Becn1 enhanced tumor
initiation and correlated with increased chromosomal alterations in vivo.
Discussion
This study is the first to directly test the role of Becn1 haploinsufficiency in an ovarian cancer
oncogenesis model. Our controlled cell-culture models of suppressed autophagy in ovarian can-
cer demonstrated increases in cellular migration, DNA copy-number instability, and genomic
evolution. Reduction of the dose of a single autophagy gene recapitulated differentially altered
pathways which are common in serous ovarian cancer [43]. Monoallelic deletion of Becn1 in an
ovarian cancer model accelerated tumorigenesis in mice, while autophagy gene knockdown
SKOV3 human ovarian cancer cells exhibited reduced autophagy gene expression, cellular
migration rates increased, γH2AX signaling was elevated, and genomic stability compromised.
Instability arose from breakage-fusion-bridge events but not increased DNA lesions nor centro-
some abnormalities. Analysis of the evolved copy-number genotypes implicated an increase in
the PI3K-Akt pathway and decreases in the Fanconi-anemia pathway, RNA degradation, Notch
signaling, and TNF signaling, mimicking pathways impacted in human serous ovarian cancer.
Autophagy acts as a tumor suppressor in ovarian cancer
Although loss of BECN1 is purported to be solely a passenger mutation "piggybacking" on a
BRCA1 deletion during tumorigenesis [12], we directly observed formation of earlier ovarian
tumors in Becn1+/- MISIIR-TAg+ mice compared to Becn1+/+ MISIIR-TAg+ mice. Context
is important [44]. BECN1 is co-deleted with BRCA1 in over 95% of cases. BRCA1 has been
readily established as a tumor suppressor through epidemiological, mutational, and knockout
mouse studies [45]. Previously reported findings suggesting that some cancers have only
BRCA1 deleted but not BECN1 deleted, fail to hold true with increased growth and precision
of the database of tumor CNAs. BECN1 was found to be deleted alone without BRCA1 deletion
in both breast and ovarian human tumors (Fig 1). The catch-all statement that "BECN1 . . . is
not a tumor-suppressor gene" [12] is not supported by the current study.
Physiological changes to cells upon autophagy gene suppression
Autophagy is a central metabolic homeostasis mechanism for cells. We tested through unbi-
ased metabolomics of lipids and energy molecules for changes upon autophagy gene knock-
down. While many aspects of metabolism remained largely unchanged, such as NAD+ and
ATP, a severe (61–74%) depletion of acetyl-CoA was observed. This correlated with an
increase in lipid content of the cells, which may aid in cell division or membrane mobility dur-
ing migration. In addition to these metabolic changes, cellular migration was enhanced in
SKOV3 cells reduced in either BECN1 and LC3B levels. High grade serous ovarian cancer,
which often originates within fallopian fimbriae, may require migration to the ovarian epithe-
lium prior to formation of invasive carcinomas [46, 47]. A suppression of autophagy may facil-
itate such a migration.
Some phenotypic changes may be specific to the genetic or epigenetic environment sur-
rounding autophagy gene knockdown. This is common in cancer studies evaluating differing
tissue types [22]. Gain-of-function studies of mutant p53 suggest genomic instability to be
dependent on the p53-interactome [48]. The observed γH2AX foci in SKOV3 cells but not
IGROV1 cells may be due to the null-expression of p53 in SKOV3 cells, although further
Autophagy Gene Haploinsufficiency Promotes Early Ovarian Tumors
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008558 January 10, 2020 14 / 28
testing is required to evaluate this possibility. The large T-antigen expressed in the spontane-
ous mouse model sequesters p53 and is hypothesized to result in a null-p53 phenotype, among
other tumor suppressors [41]. Phenotypes may be exacerbated by other mutations, such as the
homozygous deletion of CDKN2A in SKOV3 cells, or the presence of an activating PIK3CA
H1047R mutation. Interpretation of the current study may be limited in scope to epithelial
ovarian tumors with a lack of p53 expression, such as the approximately one-third of serous
ovarian cancers with nonsense or frameshift TP53 mutations [49].
The role of haploinsufficiency
Homozygous deletions are exceedingly rare in tumor cells (<1% of genes, compared to 25–
80% of genes which are 1N or 3N in serous ovarian tumors). Serendipitously, Becn1 has only
been studied for haploinsufficient tumor suppressor roles in vivo due to the early embryonic
lethality of homozygous deletion [11]. Becn1 heterozygous deficient mice exhibit defects in
autophagy, but no altered rates of apoptosis [10, 11], though Becn1 haploinsufficiency compro-
mises chromosomal stability [34]. A key difference between previous studies which showed
tumor suppressor roles and those which showed oncogenic roles of autophagy is remarkably
consistent: tumor suppressor roles are supported by evidence from heterozygous knockout or
shRNA suppression models, whereas oncogenic roles are supported by homozygous knockout
models. In the MMTV-Wnt1 model, Becn1+/- mice progress much faster; median survival was
4 mo compared to Becn1+/+ mice at 7.2 mo [50]. Future studies which claim oncogenic roles
of autophagy should include at least one model which does not require homozygous essential
autophagy gene knockouts.
Genomic instability following autophagy suppression
It is reasonable to conclude from our studies that normal dosage of BECN1 and LC3B both
enable genomic stability. Following an initial stimulus of BECN1 or LC3B reduction. we
detected widespread focal and large CNAs which were BECN1-specific as well as associated
with LC3B. Human serous ovarian cancer CNAs partially derive from foldback-inversions:
copy-number errors which occur following a breakage-fusion-bridge cycle [51]. The passaged
SKOV3 autophagy gene knockdown cells indicated many telomeric break points (Fig 2E), con-
sistent with foldback-inversions. Most genotoxic stresses induce autophagy through direct or
indirect mechanisms. It is tempting to speculate that compromised autophagy (and mito-
phagy) simply results in an accumulation of defective mitochondria. The resultant released
reactive oxygen species [52] would promote ssDNA and dsDNA breaks [53]. However, partic-
ularly in the case of BECN1, other possibilities exist. BECN1 is implicated in location specific
roles modulating kinetochore and centromeric protein maintenance [35], which may explain
why some autophagy markers do not change upon BECN1 suppression [25], despite the
observed functional phenotypes. Proteins which interact with BECN1 are enriched for chro-
mosome organization and sister chromatid cohesion proteins (S2 Table).
It may be unexpected to find any phenotypes in cell line models containing shLC3B, since
the LC3 family include three orthologs to LC3B: LC3A, LC3B2, and LC3C. The GABARAP,
GABARAPL1, and GABARAPL2 proteins also contain amino acid sequence homology. Both
LC3 family and GABARAP family proteins bind many of the same targets, including p62/
SQSTM1 and NBR1 [54]. Hence, a modest reduction in just one of four LC3 orthologs may
not be predicted to have any phenotype. However, there is evidence that LC3B punctae do not
overlap LC3A punctae, whereas LC3A and LC3C punctae do overlap, suggesting LC3B may
have unique and non-redundant functions in cancer cells [55]. While it is beyond the scope of
the current study, evaluating the molecular and phenotypic differences between LC3 family
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members in the context of cancer is warranted. LC3 family interaction networks identified
numerous unique targets which have been validated to have autophagy-independent roles
[56]. Surprisingly, our data show that modest reduction of LC3B yields oncogenic phenotypes
in ovarian cancer, similar to reduction of BECN1.
Methods
Ethics statement
All animal protocols were approved by the IACUC of University of California San Diego
(S05356), of Duke University (A225-17-09), and of Medical University of South Carolina
(00639).
Cell culture, cell lines, and reagents
Established cell lines were purchased from the American Type Culture Collection (ATCC) and
validated by short tandem repeat (STR) profiling (Promega). Routine microscopic morphol-
ogy tests were performed prior to each experiment. Cells were verified to be mycoplasma nega-
tive by a PCR assay (Agilent Technologies (Stratagene), cat# 302008). All cells were grown in
RPMI (Life Technologies) supplemented with 2% glucose, nonessential amino acids (Media-
tech #45000–700), sodium pyruvate (Mediatech #45000–710), antibiotics (penicillin, strepto-
mycin, and amphotericin, Mediatech #30-004-CI), and 10% FBS (Omega Scientific #FB-11).
For all shRNA experiments, puromycin (VWR #IC1005521) was added to 1μg/ml in RPMI.
Cells were cultured at 37˚C with 5% CO2. Antibodies. LC3B (Novus Biologicals #NB100-2220),
BECN1 (SantaCruz sc-11427), GAPDH (GeneTex #239), BRCA1 (ABclonal #A0212), and
DyLight secondary (1:15,000 dilution) antibodies were used: 800nm for anti-rabbit (VWR
#PI35571) and 680nm for anti-mouse (VWR # PI35518). Secondary HRP antibodies were
anti-rabbit (Jackson ImmunoResearch #211-032-171), or anti-mouse (Jackson ImmunoRe-
search #115-035-003). spCas9 deletion of MAP1LC3B was performed using TTCAAGCA
GCGCCGCACCTT sgRNA in a PX459 backbone. Knockdown shRNAs. Knockdowns for
MAP1LC3B and BECN1 were purchased from Thermo Fisher Scientific (#RHS4533-EG8678).
Two shRNAs were always used to generate the presented figures: TRCN0000033550 (CCGA
CTTGTTCCTTACGGAAA) and TRCN0000033552 (CTCAAGTTCATGCTGACGAAT) for
shBECN1, TRCN0000153286 (GAGTAGAAGATGTCCGACTTA) and TRCN0000155850
(CGCACCTTCGAACAAAGAGTA) for shLC3B.
Mouse models
TgMISIIR-TAg-DR26 mice were a generous gift from the Connolly laboratory [42]. Becn1+/-
mice originated from JAX laboratories, stock #018429, B6.129X1-Becn1tm1Blev/J, thanks to a
deposition by Beth Levine. To generate Becn1+/- MISIIR TAg mice, female Becn1+/- dams
were mated with MISIIR TAg sires. All experiments were performed with littermates and
genotypes were confirmed by PCR. All animal protocols were approved by the IACUC of
UCSD, and all rules and regulations were followed during experimentation on animals. The
ultrasound experiment was powered to detect differences of 30% (http://homepage.divms.
uiowa.edu/~rlenth/Power/). After genotyping, the mortality cohort of 13 TAg and 20 BTAg
mice was predicted to have 78% power to detect 15% change in median survival with a 15%
standard deviation. Ultrasound was performed in the UCSD Moores Cancer Center mouse
imaging core, using a high resolution Vevo 2100 (FUJIFILM VisualSonics Inc). No blinding
was performed, since mice were visually distinguishable by lighter fur coat color. All mice
were female. Euthanasia criteria for the mortality experiments included loss of 20% of body
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weight, impairment of gait which prevented feeding or water consumption, or visible disten-
sion of abdomen indicating ascites.
Western blotting
Cells were grown to 80% confluency on 10cm plates at 37˚C. Media was aspirated, cells washed
in PBS, and the cellular monolayer was immersed in iced RIPA buffer (supplemented with a
protease inhibitor cocktail (Sigma-Aldrich), 2 mM sodium orthovanadate, and 50 mM NaF).
Following 15 minutes at room temperature (to better extract LC3 [9]), lysates were collected
using a cell lifter (Fisher Scientific). Lysates were spun at 10,000g for 10 minutes at 4˚C and
supernatant saved and quantified by BCA assay (Pierce #23235). 10–30μg protein was loaded
per well of a 15% SDS-PAGE gel and transferred onto PVDF membrane. The membrane was
blocked in 5% dry milk (Genesee Scientific, #20–241). Primary antibodies were used at 1:1000
dilution, and secondary HRP antibodies were used at 1:5,000 dilution or secondary fluorescent
antibodies were used at 1:15,000. Fluorescent secondary antibodies were visualized using a
LI-COR Odyssey scanner. Quantitation of band intensity was performed in ImageJ and all
normalizations were to the loading control displayed in the corresponding figure.
Flow cytometry
Acridine orange staining was performed identically as previously described [16]. HAPTRIG
scores used for comparison were generated from CCLE copy-number alterations downloaded
from the UCSC Xena Browser, as previously described using default HAPTRIG settings [16].
Microarray analysis of copy-number alterations
Human SKOV3 cell lines were assayed for copy-number alterations using an Affymetrix
OncoScan array. CEL files were processed by the Affymetrix chromosome analysis suite
according to manufacturer’s instructions. Ploidy was verified and normalized in part by the
known single allele of chromosome 7 and homozygous deletion of CDKN2A. Segmentation
was performed from within the Affymetrix analysis suite. Since SKOV3 already contains
CNAs and our experimental question was whether or not spontaneous CNAs formed in this
model, we used the reduced segment method in CNTools (V1.32.0) [57] to create regions of
differential copy-numbers. The mean segment amplitude of all four SKOV3 shScr replicates
was used as the “normal” reference in the experiment, and all new CNAs were called if the
magnitude was at least 0.2 units deviant from the normal.
Sequencing analysis of murine copy-number alterations
Mice were euthanized according to the tumor burden requirements elucidated in the survival
analysis section. Tumors were immediately resected, imaged, and snap frozen in liquid nitro-
gen. Tumors were stored in a -80˚C freezer. For DNA extraction, tumors were individually
thawed and processed by a Qiagen Blood and Tissue DNA kit, according to manufacturer’s
instructions. Uterus tissue was removed and physically cleared of any tumor tissue and identi-
cally processed as normal adjacent tissue controls. DNA was then processed by the University
of California San Diego Institute for Genomic Medicine sequencing core, according to normal
Illumina protocols. DNA was sequenced for low-pass whole-genome coverage on an Illumina
HiSeq4000 (~4Gb per sample) at the IGM Genomics Center, University of California, San
Diego, La Jolla, CA. Paired-end reads were mapped to reference mm10 genome using Bowtie2.
Mapped reads were input into HMMcopy (V1.18.0) [58], along with mappability and GC cor-
rection files as instructed by the HMMcopy package. Default settings were used to determine
Autophagy Gene Haploinsufficiency Promotes Early Ovarian Tumors
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008558 January 10, 2020 17 / 28
CNAs compared to normal tissue controls. Normal tissue was found to be essential in accu-
rately determining segmented regions; without normal tissue controls many false positives are
observed across all samples. A custom R script was written to produce the graphical outputs
shown in S10 Fig.
Quantitation of break site features
A custom R script was written to compare the distance of CNA edges observed in the SKOV3
cells to known features on the hg19 reference genome. These features include fragile and stable
DNA sites from [59]. Regions within 2Mb of telomeres and centromeres as annotated by the
UCSC Genome Browser were considered telomeric or centromeric breaks. Gene locations
were annotated as from the first exon to then end of the last exon, including introns. Compari-
sons to randomized segments were performed by randomly moving equal sized segments of
the observed segments on iso-chromosomal locations for 1,000 permutations and outputs
included overlapping gene size or expression. Expression values were pulled from the CCLE
dataset of the SKOV3 sample, downloaded from the UCSC Xena Browser.
CAIRN database and accessibility
CAIRN was developed with the intent to distribute an easy-to-use tool for scientists with lim-
ited or no bioinformatic background to analyze copy-number variation around a locus of
interest. It is available to use online for free at https://delaney.shinyapps.io/CAIRN/. For more
complex or systematic use of the tool, code is available by download from https://github.com/
jrdelaney/CAIRN. The Shiny R App is included within the zip package and installation and
usage instructions are included within the zip file in pdf format. All included CNA data for
default cancers online are from TCGA white-listed samples with segment information down-
loaded from the Genomic Data Commons: the PanCanAtlas summary (https://gdc.cancer.
gov/about-data/publications/pancanatlas). Custom human data is enabled by uploading into
the App or into the online version. Currently coordinates are set to hg38, but can be changed
by altering files from the downloaded App.
Clinical and genetic characteristics analysis
Tumor stage, racial group, age at diagnosis, and number of somatic mutations were taken
directly from TCGA summary spreadsheets downloaded from cBioPortal [20]. Genome
altered (%) was calculated from TCGA gene-level summary CNA data wherein only genes
were considered, not intergenic regions or acrocentric chromosome arms (eg, 13p). Percent
genome altered is thus based on the percent of genes with alterations, not the percent of the
length of chromosomes altered. Survival plots were generated using KmPlot [60], since the
number of samples exceeds TCGA data. For RNA expression cutoffs, the automatic cutoff
selection criterion was used. For autophagy pathway-level Kaplan-meier analysis, HAPTRIG
calculations of the lowest scored tertile was plotted against the highest scored tertile using sur-
vival and survminer R software packages.
Fluorescence microscopy
For acridine orange staining, 10,000 cells were seeded in wells in a 96-well tissue-culture plate
(VWR, #10062–900) in 100μL phenol-red free RPMI (Fisher Scientific, #11835030) media con-
taining 4μg/mL puromycin. Media was not supplemented with non-essential amino acids nor
sodium pyruvate. The day of imaging, 10μM chloroquine phosphate (VWR, #AAJ64459-14),
10nM rapamycin (LC Labs, R-5000), both, or control vehicle were added to the cells. Four
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hours later, acridine orange (Fisher Scientific, #AAL1315906) was added to 0.3μg/mL. Cells
stained in the tissue culture incubator for 30 minutes prior to imaging. The plate was then
imaged in the Texas Red channel in a BioTek LFX microscope using a 20X objective. For
quantitation, ImageJ was used. The “Find maxima” function was used to identify acridine
orange punctae, using individually selected cells. Two assays were performed and at least 100
cells from multiple fields quantified per condition.
For anaphase bridge counting, cells with stable integration of shScr, shBECN1, or shLC3B
were seeded at 25,000 cells per well in a Nunc Lab-Tek II Chambered Coverglass, 8-well cham-
ber slide (Thermo Scientific, #155409). For anaphase bridge assays, cells were grown for two
days on the chamber slide, media was aspirated, 500μL of PBS slowly added and then aspirated,
and 4% paraformaldehyde added for 15 minutes at room temperature. Cells were then washed
once with PBS and stained for 30 minutes with Hoescht 33342 (1μg/mL in PBS). Cells were
washed twice in PBS and mounted in 20μL VectaShield Antifade Mounting Medium (Vector
Laboratories, #H-1000). Slides were imaged on a Nikon Eclipse 80i with a 40X objective or a
BioTek LFX with a 20X objective and then pictures were blinded for anaphase bridge scoring
analysis. Statistical comparisons were made using a Fisher’s Exact test.
For gamma-tubulin staining, cells were grown and processed similarly, but additionally
permeabilized for 2 minutes with 0.1% Triton X-100 in PBS, blocked with 5% BSA / 5% goat
serum for 30 minutes, stained with 488-conjugated γ-Tubulin (Fisher Scientific, #
NB11090616X) for 1 hour RT and 16 hours 4˚C, and washed 3x 30 minutes in PBS prior to
mounting with VectaShield. Slides were imaged were imaged on a Nikon Eclipse 80i with a
40X objective.
For γH2AX staining, cells were grown to ~80% confluence. For cisplatin treated cells, cells
were treated 48 h prior to fixation (13μM for SKOV3). Cells were washed with 50 μL PBS and
then aspirated. Cells were fixed in 50μL of 4% PFA in PBS for 10 minutes and then 50 ul of
0.1% Triton X-100 in PBS for 2 minutes. The cells were washed again in 50 μL PBS. To block,
50μL of 5% bovine-serum-albumin (BSA, VWR #97061–416) and 5% goat-serum (GS, VWR
#102643–594) in PBS was added to the cells and rocked for 45 minutes at room temperature.
Supernatant was aspirated and 50μl of primary antibody solution (anti-H2AX phospho-Ser139
(Biolegend #613402) diluted 1:1000 with 5% BSA/GS in PBS) was added and rocked overnight
at 4˚C. The primary antibody solution was removed, and the cells were washed with 50μl PBS
once followed by three additional 5-minute PBS washes. The cells were stained in 50μL of sec-
ondary antibody solution (Alexa Fluor 647 goat anti-mouse (Invitrogen #A21236) diluted
1:1000, Hoechst 33342 diluted 1:10,000, 5% BSA/GS in PBS), for 1.5 hours. The secondary
antibody solution was removed, and cells were washed with one quick wash, three 5-minute
washes, and one 30-minute PBS wash. Cells were imaged on a BioTek LFX microscope using
DAPI and CY5 filters at 20x magnification, automatic focus, and equal exposure time. For
analysis, FIJI was used [61]. Within each nucleus, the maxima function was used to identify
punctae and the measure function analyzed each puncta’s intensity.
For cellular migration assays, shScr, shBECN1, shLC3B plasmids were transduced into
SKOV3 and IGROV1 cells. Cells were selected with 2μg/ml puromycin. Cells were seeded into
a 24-well tissue culture plate for IGROV1 (800k cells) and SKOV3 (600k cells) to reach conflu-
ence after 24-48h of growth. A P-10 pipette tip was used to create scratch wound. Images were
captured every 2 hours for 24–48 hours on the BioTek LFX microscope and the area of the
scratch wound was quantified using ImageJ. The percent of the wound remaining was calcu-
lated by dividing the area of the scratch at a given time point by the area at time 0. Subtracting
the percent remaining from 100% yielded the percent closure at each time point. To obtain a
relative rate, calculations divided by shScr rates.
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Comet assays
Cells were processed according to manufacturer’s protocol in the CometAssay Kit (Trevigen,
#4250-050-K) using Alkaline preparation conditions. Staining was performed using SYBR
Green 1X (from 10,000X stock, Thermo Fisher #S7563). Lysed nuclei comets were imaged on
a Nikon Eclipse 80i at 40X and analyzed by OpenCOMET [62] for percentage of DNA in the
tail moment.
Metabolomics
All samples were grown to 80% confluency on a 10cm tissue culture dish. Cells were harvested
by trypsinization and neutralized with iced RPMI complete media. Cells were washed twice in
iced PBS and split into two tubes. Cell pellets were saved at -80˚C until analysis. All sample sets
had three independent cell growth experiments performed on different days.
For amino acid and lipid analysis, tubes containing ovarian cancer cell pellets were thawed
at room temperature and then stored on ice during manipulation. For normalization, a dupli-
cate pellet was analyzed by BCA assay for total content determination. 100 μL of 80/20 v/v
MeOH/water was added to each sample tube. Samples were then probe sonicated 3 times at
power level 3 for 5 seconds each burst, cooling on ice between bursts. Samples were then
allowed to incubate for 10 minutes while on ice and then put in -80˚C freezer until ready for
analysis.
Samples were prepared using the AbsoluteIDQ p180 kit (Biocrates Innsbruck, Austria) in
strict accordance with their detailed protocol. Samples were taken from the -80˚C freezer and
centrifuged at 4˚C for 10 minutes at 15,000g. After the addition of 10 μL of the supplied inter-
nal standard solution to each well of the 96-well extraction plate, 15 μL of each ovarian study
sample was added to the appropriate wells. The plate was then dried under a gentle stream of
nitrogen for 10 minutes. An additional 15 μL of each study sample was added to the respective
wells and plate was dried under nitrogen for an additional 20 minutes. The samples were
derivatized with phenyl isothiocyanate then eluted with 5mM ammonium acetate in methanol.
Samples were diluted with either 1:1 methanol:water for the UPLC analysis (4:1) or running
solvent (a proprietary mixture provided by Biocrates) for flow injection analysis (20:1).
A study pool sample was created (5041 SPQC) by taking an equal volume from each study
sample. The pooled sample was prepared and analyzed in the same way as the study samples in
triplicate. On the kit plate, the SPQC was prepared in triplicate; one of these preparations was
analyzed in triplicate while the other two were analyzed in a staggered manner before, during,
and after the study samples in order to measure the performance of the assay across the sample
cohort. The five analyses of this pool can be used to assess potential quantitative drift across
the analysis of the plate, or in larger studies, to assess batch effects.
UPLC separation of amino acids and biogenic amines was performed using a Waters (Mil-
ford, MA) Acquity UPLC with a Waters Acquity 2.1 mm x 50 mm 1.7 μm BEH C18 column
fitted with a Waters Acquity BEH C18 1.7 μm Vanguard guard column. Analytes were sepa-
rated using a gradient from 0.2% formic acid in water, to 0.2% formic acid in acetonitrile.
Total UPLC analysis time was approximately 7 minutes per sample. Acylcarnitines, sphingoli-
pids, and glycerophospholipids were analyzed by flow injection analysis (FIA) with total analy-
sis time of approximately 3 minutes per sample. Using electrospray ionization in positive
mode, samples for both UPLC and flow injection analysis were introduced directly into a Xevo
TQ-S triple quadrupole mass spectrometer (Waters) operating in the Multiple Reaction Moni-
toring (MRM) mode. MRM transitions (compound-specific precursor to product ion transi-
tions) for each analyte and internal standard were collected over the appropriate retention
time. The UPLC-MS/MS data were imported into Waters application TargetLynx for peak
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integration, calibration, and concentration calculations. The UPLC-MS/MS data from Targe-
tLynx and FIA-MS/MS data were analyzed using Biocrates MetIDQ software. For statistical
comparisons of glycerophospholipids and sphingolipids, a Wilcoxon rank-sum test was per-
formed. All other tests were a student’s t-test.
For the energy metabolites including Acetyl-CoA, NAD+, Glutathione, cAMP, AMP, ADP,
and ATP, an alternate assay was performed on the same cell pellet following the sonication
step. The samples were then placed in a cold aluminum sample block on dry ice and incubated
for 10 minutes. Next the samples were centrifuged for 10 minutes at 4˚C and 15,000 g and
stored at -80˚C until ready for analysis. The samples were warmed to 4˚C on ice and centri-
fuged again for 10 minutes at 4˚C and 15,000 g to pellet any solids. Forty microliters of super-
natant from each sample was pipetted into a glass total recovery vial (Waters) labeled with its
corresponding DPMSR ID number. The remaining pellet from each sample was stored at
-80˚C. A study pool quality control (SPQC) sample was prepared by combining 5 μL of super-
natant from each sample into a 1.5 mL tube (Eppendorf). Stable Isotope Labeled (SIL) standard
material, the 13C Credentialed E. coli kit (MS-CRED-KIT) was purchased from Cambridge
Isotope Laboratories. This is an E. coli extract from uniformly 13C-labeled E. coli. The material
was tested to have minimal to no contributing signal in the light channel, using injections of
only the 13C-labeled standard in previous experiments. Nine hundred microliters (900 μL) of
sample resuspension solvent was created by taking one vial of 13C-labeled MS-CRED-KIT
containing 100 μL of lysate and adding 400 μL of 80:20 v/v methanol/water. This resuspension
solution was prepared immediately before addition to the samples. This solution was also used
as the internal standard blank during the analysis. Ten microliters of the 13C-labeled E. coli
resuspension solution was added via repeater pipette to each sample in the glass total recovery
vials. Four microliters from each sample was injected for analysis by LC-MS/MS.
Liquid chromatographic separation was performed using a Waters Acquity UPLC with a
2.1 mm x 30 mm, 1.7 μm pore size ethylene bridged hybrid (BEH) amide column (Waters PN:
186004839). Mobile phase A was composed of water with 10 mM ammonium hydrogen car-
bonate (AmBic) (Millipore Sigma, St. Louis, MO) containing 0.2% ammonium hydroxide
(NH4OH) generated as follows: 3.34 mL of 30% ACS grade NH4OH was added to 1 L water,
followed by the addition of 0.3982 g AmBic. Mobile phase B was neat acetonitrile (Optima
LCMS grade Thermo). The weak needle wash was mobile phase B and the strong needle wash
was mobile phase A. The total length of the LC Gradient Program is 5.00 minutes. The outlet
of the analytical column was connected directly via electrospray ionization into a Xevo TQ-S
mass spectrometer (Waters) with positive/negative mode switching. Retention time scheduling
with 30 second windows was used to minimize concurrent MRM transitions, and automatic
dwell calculation was used to maximize dwell time while maintaining at least 8 points across
the chromatographic peak. Eighty milliseconds (80 msec) was set as the polarity-switching
delay. Positive and negative ion electrospray were alternated during the entirety of an LC gra-
dient program for one injection. In ESI+ mode, capillary voltage was 3.0kV, source offset was
50V, desolvation temperature was 400˚C, desolvation gas flow was 650 L/hr N2, cone gas was
150 L/hr N2, and nebulizer pressure of 7.0 bar was used. Source parameters for ESI- ionization
were the same as ESI+, with the exception of the capillary voltage was set to -2.0 kV. Each sam-
ple was analyzed in Multiple Reaction Monitoring (MRM) mode in the mass spectrometer
during the LC gradient program as ions eluted from the LC column.
Statistics
In all figures, �P� 0.05, ��P� 0.01, ���P� 0.001 and ns P> 0.05. Error bars represent s.e.m.
unless otherwise indicated. In vivo comparisons were made by Wilcoxon rank-sum tests. All
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other P values were calculated using a two-tailed student’s t-test unless otherwise noted. For
HAPTRIG tool statistics, 1,000 genome-wide permutation simulations were used and P values
from Wilcoxon rank-sum comparisons to these permutations were used to calculate signifi-
cant differences from expected pathway perturbations caused by randomly permuted gene
sets.
Supporting information
S1 Fig. Examples with CAIRN. A, CAIRN tested for co-amplifications of the oncogenes MYC
and PTK2 (PTK2 is better known by its encoded oncoprotein FAK). B, Pie charts of CAIRN
amplification findings. Coincident CNAs do not always dominate exclusive CNAs of onco-
genes, however, co-amplification is also common on the same chromosome arm.
(TIF)
S2 Fig. LC3B genetic changes in ovarian (OV) and breast (BRCA) TCGA tumors. CAIRN
was used to quantify and display copy-number alterations in serous ovarian cancer and breast
cancer cohorts studied by the TCGA. All CNA-available tumors are shown in the top panels,
whereas those with corresponding SNV data are shown in the bottom panels, with CAIRN
markings for tumor suppressors (black) and oncogenes (green) in patients with the indicated
CNA event.
(TIF)
S3 Fig. Clinical and genetic characteristics associated with autophagy gene loss. A, Racial
group proportion data are plotted for patients with primary tumors containing a loss in one of
LC3B or BECN1, both, or neither. A fisher’s exact test was performed on the White racial
group against all other groups, with a P> 0.05 indicated by “ns”. B, Similarly, Stage data were
tested for differences. In the fisher’s exact test, the largest group (stage III) was tested against
all other groups. All comparisons were P> 0.05, “ns”. C, The age at diagnosis were compared
by Wilcoxon rank-sum test, with P> 0.05 indicated by “ns”. D, Somatic mutation counts were
compared by Wilcoxon rank-sum test. E, Percent genome altered per tumor group were com-
pared to the “neither” group by Wilcoxon rank-sum test, with ��P� 0.01. Boxplot error bars
represent furthest outliers. F, KmPlot outputs of human SOC tumors with or without at least
one loss of the BECN1 gene, the MAP1LC3B gene, or either gene. G, KmPlot outputs of
human SOC tumors with high or low expression of the indicated autophagy genes. H, Kaplan-
Meier plot of TCGA SOC (OV) tumors analyzed by HAPTRIG for the autophagy pathway,
with low and high levels of pathway scores separated by tertiles.
(TIF)
S4 Fig. Copy-number profiles of common ovarian cancer cell lines. Segmented data were
downloaded from the UCSC Xena Browser for the CCLE and NCI-60 lines. Displayed are
CNAs visualized by IGV. For reference, TCGA OV tumors are also displayed.
(TIF)
S5 Fig. Acidic organelles have impaired turnover with autophagy gene knockdown. A,
SKOV3 cells were tested for accumulation of AO following treatment of an autophagy inducer
(Rapa, rapamycin), an autophagosome clearance inhibitor (CQ, chloroquine), or both, for 4 h.
B, Quantitation of the microscopy data shown in (A). C-D, Similar tests as in (A,B) with
IGROV1 cells.
(TIF)
S6 Fig. Metabolomics with autophagy gene knockdowns. A, Lysate immunoblots from three
independently created, passaged, and pelleted SKOV3 cells containing lentiviral incorporation
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of the indicated shRNAs. Lysates immunoblotted were from the identical samples as those sub-
mitted for metabolomics analysis. N = 6 per condition, from three experiments with two bio-
logical replicates. B, Quantitation of the immunoblots. C-G, Individual metabolites were
compared to shScr controls. �P� 0.05, and error bars represent s.e.m. H, Cell lysate immuno-
blots of SKOV3 cells and a clone modified by CRISPR-Cas9 to eliminate LC3B. I, Comparison
of all shown metabolites between shBECN1 and shLC3B averages with a linear correlation
model shown. J, Comparison of all shown metabolites between Cas9-knockout LC3BΔ and
shLC3B averages with a linear correlation model shown.
(TIF)
S7 Fig. Unaffected oncogenic phenotypes. A, Scratch wound migration assay of confluent
IGROV1 cells. Note the slower timeline compared to SKOV3 cells. Quantitation includes
N = 8 replicates from two independent experiments. B, A crystal violet growth assay confirmed
trends in (A) were not due to enhanced growth rate. Shown is a representative experiment of
two independent experiments, with four biological replicates. C, SKOV3 cells transduced with
the corresponding shRNAs were tested by alkaline comet assay for ssDNA and dsDNA breaks.
N> 50 cells per condition, from three independent assays. D, SKOV3 cells knocked down for
LC3B or BECN1 were tested for centrosome size abnormalities by γ-Tubulin staining.
N> 100 cells per condition, from two independent assays. E, Immunoblot of SKOV3 and
IGROV1 cells transduced with BECN1 targeting shRNA. The neighboring gene BRCA1 was
tested for alterations in protein levels. F, IGROV1 cells were imaged for γH2AX puncta.
N> 1100 cells from two independent assays.
(TIF)
S8 Fig. Autophagy knockdown increases focal and megabase CNAs. A, Genomic DNA from
the 30 passage SKOV3 cells from was profiled using high-density Oncoscan arrays and ana-
lyzed for copy-number changes (Fig 4). Copy-number alterations (CNAs) were quantified for
each sample by size. Genome-wide CNAs were summed and graphed for each biological repli-
cate. �P� 0.05, ��P� 0.01, ���P� 0.001, by Wilcoxon rank-sum test. B, CNA counts for indi-
vidual chromosomes are displayed.
(TIF)
S9 Fig. Becn1+/- tumor morbidity. Complements Fig 6, the MISIIR Large-T-Antigen (TAg+)
ovarian cancer mouse model. A, Littermate mice were euthanized according to morbidity:
either difficulty moving, 20% weight loss, or development of ascites. While there was a trend,
Becn1+/- TAg and littermate control Becn1+/+ TAg mice did not have statistically significant
differences in cancer-related morbidity with the sample number tested. B, Copy-number anal-
ysis for the Brca1 region of TAg+ tumors with or without Becn1 heterozygous deletion. No
CNA deletions overlapped Brca1 in the four tumors tested from each group.
(TIF)
S10 Fig. Whole-genome copy-number alteration plots of murine tumors. Terminal tumors
shown in Fig 6 were harvested for genomic DNA and processed on an Illumina HiSeq4000 for
whole-genome DNA reads. Data were controlled for GC content and mappability. In addition,
each tumor’s DNA was then normalized to control normal tissue: adjacent uterus. Copy-num-
ber was determined by HMMcopy, using 500kb windows (containing 1000–2000 reads per
window). A custom R script was used to use HMMcopy outputs and plot the visual copy-num-
ber changes shown here. Red indicates a gain of magnitude 0.2 or more (log2 units), blue indi-
cates a loss of magnitude 0.2 or more.
(TIF)
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S1 Table. Genes altered by CNAs in the SKOV3 spontaneous evolution experiment. Each
sample is tabulated for its log2 ratio copy-number difference from the mean of all four shScr
samples. Additionally, a second sheet describes which genes were affected by gene-breakage
wherein a CNA end occurs within the coding region. HAPTRIG pathway information is tabu-
lated here.
(XLS)
S2 Table. Proteins which interact with BECN1 are enriched for chromosome organization
and sister chromatid cohesion genes. BioGrid was used as a resource for protein-protein
interactions. GO term enrichment was tested by the GOrilla online tool (cbl-gorilla.cs.tech-
nion.ac.il) using all human genes found in BioGrid as a background list.
(XLS)
S3 Table. Segmented data and gene-level analysis of CNAs found in the mouse tumor
DNA experiments. Each sample is tabulated for its log2 ratio copy-number difference as
determined by HMMcopy.
(XLS)
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